NEW YORK (GenomeWeb News) – Helicos BioSciences has filed a prospectus with the US Securities and Exchange Commission on behalf of selling shareholders offering around 6.6 million shares of the firm's common stock.
The firm will offer the resale from time to time of up to 6,633,789 shares of its common stock, with 2,322,509 of those shares issuable upon exercise of warrants. Helicos is not selling any securities in the offering and will not receive any of the proceeds from the selling shareholders.
The total shares of common stock being offered, including the warrants, is the same number of shares that the firm recently issued in a private placement that netted Helicos $9.4 million in proceeds.
Among the investors in that private placement that are also listed in the prospectus as potential selling shareholders are Atlas Ventures, Flagship Ventures, Highland Capital Partners, Versant Ventures, and the firm's CEO, Ron Lowy. Also listed in the prospectus as potential sellers are other investors including Empery Asset Management, Capital Ventures International, Hudson Bay, RA Capital Healthcare Fund, and Ramius.
Helicos notes in the prospectus that the selling shareholders may "sell some, all or none of their shares."
In early Thursday trade on the Nasdaq, Helicos' shares were down 2 percent at $2.81.